When I was diagnosed in ’94, I had never heard of multiple myeloma (MM). It is important to read the medical definitions for multiple myeloma such as the symptoms, therapies, and prognosis. To learn more about the key questions that Multiple Myeloma patients need to ask click the link below:
Your oncologist has probably told you that myeloma is incurable but very treatable. You may be wondering what “very treatable” means. Yes, there is a long and growing list of FDA approved chemotherapy regimens for MM. It is important to know that induction chemotherapy cocktails such as RVD (revlimid, velcade, dexamethasone) will put you into remission.
But if you want to know about the evidence-based, non-toxic, anti-MM therapies that have kept me in complete remission from my MM since 1999, read on.
Multiple myeloma, also known as plasma cell myeloma, is a cancer of plasma cells, a type of white blood cell normally responsible for producing antibodies. Initially, there are often no symptoms. When advanced, bone pain, bleeding, frequent infections, and anemia may occur.
According to the American Cancer Society the average MM survival is 3-5 years depending on stage at diagnosis. The standard of care for newly diagnosed MMers is induction chemotherapy, an autologous stem cell transplant (ASCT) and low-dose maintenance therapy.
Multiple Myeloma patients and survivors usually don’t die from their cancer. They die from health problems caused by their cancer such as bone damage and/or from the toxicity caused by chemotherapy and radiation.
The solution? Take an integrative approach to managing your multiple myeloma. Enhance the efficacy of chemotherapy and while you reduce the toxicity.
What have I learned about MM over the past 20+ years? Myeloma is about two things:
1) symptoms (bone damage, anemia, kidney function, etc.)
2) side effects from toxic chemotherapy.
Whether you are debating treatment options, currently undergoing treatment and experiencing painful side effects, or trying to figure out how to stay in remission, evidence-based therapies are the key.
Please watch the video below to learn more about the evidence-based, integrative therapies to combat treatment side effects and enhance your chemotherapy.
“Based on a review of these studies, it is evident that better bioavailability of formulated curcumin (CU) products is mostly attributed to improved solubility, stability, and possibly low first-pass metabolism”
A search of the Pubmed database for the word curcumin yields 601 studies spaning health topics from multiple myeloma and colorectal cancer, to chemotherapies that synergizes with CU, to Alzheimer’s Disease, arthritis and more. Based on years of reading studies and personal accounts, I think it is safe to say that CU supplementation is safe and relatively inexpensive.
I have read about myeloma patients taking daily doses of CU from 400 milligrams to 8 grams (1000 milligrams = 1 gram). By almost any measure, CU is a safe, inexpensive wonder drug.
The only challenge is that CU is famously difficult to absorb in the body. In other words, a person has to mix curcumin with some sort of fat (coconut oil, chocolate, etc.) or take a brand of curcumin capsule that is already formulated to be more “bioavailable” in order to derive the full benefit of CU.
The study linked and exerpted below reviews different formulations of CU. The study itself lists the three most bioavailable formulation/brand of CU and I’ve added an excerpt from a further review from Consumerlab.com that lists four additional bioavailable brands of CU.
“CU is a bright yellow chemical produced by some plants. It is the principal curcuminoid of turmeric (Curcuma longa), a member of the ginger family, Zingiberaceae. It is sold as an herbal supplement, cosmetics ingredient, food flavoring, and food coloring.“
“Curcumin is a widely studied natural compound which has shown tremendous in vitro therapeutic potential. Despite that, the clinical efficacy of the native CU is weak due to its low bioavailability and high metabolism in the gastrointestinal tract. During the last decade, researchers have come up with different formulations with a focus on improving the bioavailability of curcumin. As a result, a significant number of bioavailable curcumin-based formulations were introduced with the varying range of enhanced bioavailability.
The purpose of this review is to collate the published clinical studies of CU products with improved bioavailability over conventional (unformulated) CU. Based on the literature search, 11 curcumin formulations with available human bioavailability and pharmacokinetics data were included in this review. Further, the data on clinical study design, analytical method, pharmacokinetic parameters and other relevant details of each formulation were extracted.
Based on a review of these studies, it is evident that better bioavailability of formulated curcumin products is mostly attributed to improved solubility, stability, and possibly low first-pass metabolism. The review hopes to provide a quick reference guide for anyone looking information on these bioavailable curcumin formulations.
Based on the published reports,
exhibited over 100-fold higher bioavailability relative to reference unformulated CU. Suggested mechanisms accounting for improved bioavailability of the formulations and details on the bioanalysis methods are also discussed.”
According to Consumerlab.com:
“Novasol has the highest bioavailability (185 x compared to unforumulated CU), followed by Curcuwin (136 x), Longvida (100 x), Meriva (48 x), BCM-95 (27 x), Curcumin C3 Complex + Bioperene (20 x), and then Theracumin (16 x).”